Roxadustat significantly increased haemoglobin levels for chronic kidney disease patients with anaemia in Phase III OLYMPUS and ROCKIES trials
8 November 2019 07:00 GMT Roxadustat significantly increased haemoglobin levels for chronic kidney diseasepatients with anaemia in Phase III OLYMPUS and ROCKIES trials OLYMPUS demonstrated a mean increase of 1.75g/dL averagedover weeks 28 to 52, compared to 0.40g/dL with placebo ROCKIES demonstrated a mean increase of 0.77g/dL averagedover weeks 28 to 52, compared to 0.68g/dL with epoetin alfa AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin (Hb) levels in non-